Biofrontera to Report First Quarter 2024 Financial Results on May 15, 2024

Biofrontera to Report First Quarter 2024 Financial Results on May 15, 2024

May 06, 2024 | Last Trade: US$0.86 0.02 2.61

WOBURN, MA / ACCESSWIRE / May 6, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three months ended March 29, 2024 on Wednesday, May 15, 2024. The results will be released after the market close on Wednesday, May 15 and the company will host a conference call on Thursday, May 16 at 10:00am Eastern Time.

Conference Call and Webcast Information

Toll Free	1-877-877-1275
International	1-412-858-5202
Webcast	Webcast \| Biofrontera Inc. First Quarter 2024 Financial Results and Business Update Conference Call (choruscall.com)

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts:

Investor Relations
Andrew Barwicki
1-516-662-9461
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$0.86
Daily Change:	0.02 2.61
Daily Volume:	63,348
Market Cap:	US$8.110M

June 03, 2025 Biofrontera Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book May 15, 2025 Biofrontera Reports First Quarter 2025 Financial Results and Provides a Business Update May 15, 2025 Biofrontera Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris March 21, 2025 Biofrontera Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update March 18, 2025 Biofrontera Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE